To meet its aspiration of becoming a life sciences superpower, the UK must not only discover and develop new medicines – it must also be able to manufacture them at scale,
Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform techn
Generic drugs are incredibly important in the medical field, not only for their effectiveness, but also for their cost-saving potential for both manufacturers and customers.
Shares in ImmunityBio were in freefall today after it revealed the FDA had rejected its marketing application for Anktiva as a treatment for bladder cancer.
Baxter has reached an agreement to sell its contract development and manufacturing organisation (CDMO) business to a pair of private equity companies, raising $4.25 billio